How do I convert a patient from Tresiba (insulin degludec) to Lantus (insulin glargine) in terms of dosing?

Converting from Tresiba (Insulin Degludec) to Lantus (Insulin Glargine)

When converting from Tresiba to Lantus, start with a unit-to-unit conversion (1:1 ratio) and closely monitor blood glucose, as clinical evidence suggests equivalent or slightly higher doses of Lantus may be needed to maintain glycemic control.

Conversion Algorithm

Initial Dose Conversion

• Start with the same total daily dose of Lantus as the patient's current Tresiba dose 1
• Administer Lantus once daily at the same time each day (can be any time, but must be consistent) 1
• The FDA label for Lantus explicitly states that when converting from other basal insulins, dose adjustments should be made cautiously under medical supervision 1

Expected Dose Adjustments

Based on real-world observational data, the conversion is not perfectly 1:1:

• Research shows that when switching from degludec to glargine, patients may require slightly higher doses of glargine to maintain equivalent glycemic control 2
• In one observational study, the relationship between degludec and glargine doses suggested approximately 78-80% of the degludec dose converts to the needed glargine dose, though this varied by patient 2
• However, start conservatively at 1:1 to minimize hypoglycemia risk, then titrate up as needed 1

Monitoring and Titration Strategy

Critical monitoring period: First 2-4 weeks

• Check fasting blood glucose daily
• Monitor for hypoglycemia, especially in the first week (degludec has a longer half-life and may still be present) 1
• Titrate Lantus dose by 2 units every 3 days to reach fasting plasma glucose goal without hypoglycemia 3
• If hypoglycemia occurs without clear cause, reduce dose by 10-20% 3

Important Clinical Considerations

Pharmacokinetic Differences to Anticipate

Tresiba has a significantly longer duration of action (>42 hours) compared to Lantus (~24 hours), which creates specific challenges:

• Residual degludec activity may persist for 3-5 days after the last dose
• Risk of hypoglycemia is highest in days 1-3 of the conversion due to overlapping insulin activity
• Conversely, risk of hyperglycemia increases after day 5-7 if Lantus dose is insufficient

Glycemic Control Expectations

Research demonstrates that:

• Fasting plasma glucose may initially rise when switching from degludec to glargine, as degludec provides more consistent 24-hour coverage 4, 5
• Nocturnal hypoglycemia rates are lower with degludec than glargine in clinical trials 4, 6, 7, so expect potentially more nocturnal hypoglycemia with Lantus
• Overall glycemic control (HbA1c) should remain equivalent if properly titrated 4, 6, 7

Practical Pitfalls to Avoid

1. Do not mix or dilute Lantus with any other insulin or solution—this alters its pharmacokinetic profile unpredictably 1
2. Do not assume the conversion is complete after one week—full steady-state of Lantus takes 2-5 days, but degludec washout takes longer
3. Adjust prandial insulin if needed: Some patients may require modest increases in mealtime insulin (approximately 10-15% increase) when switching from degludec to glargine 2
4. Consider patient-specific factors: Patients with renal impairment, variable meal patterns, or history of hypoglycemia unawareness need more conservative conversions

Special Populations

Type 1 Diabetes

• More aggressive monitoring required
• Consider reducing initial Lantus dose to 90% of degludec dose if patient has history of hypoglycemia
• Ensure adequate prandial insulin coverage is maintained 3

Type 2 Diabetes

• Generally more forgiving conversion
• Can typically use 1:1 conversion safely
• Monitor for need to uptitrate within 1-2 weeks 6

Patients with High Glycemic Variability

• Evidence suggests these patients may experience increased variability when switching from degludec to glargine 8
• Consider more frequent glucose monitoring (CGM if available)
• May need higher final Lantus dose than original degludec dose

The key principle: Start conservatively at 1:1, monitor intensively for the first week for hypoglycemia, then titrate upward as needed over the following 2-3 weeks to achieve fasting glucose targets 1, 2.